Therapeutic Potentials of İnhibition Jumonji C Domain Containing Demethylases in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a complex disease affected by both genetic and epigenetic factors. The histone methylation and demethylation are types of epigenetic modification in chromatin remodeling and gene expression. Abnormal expression of histone demethylases is indicated in many types of cancer including AML. Although many commercial drugs are available to treat AML, the absolute cure is not discovered yet. However, inhibition of demethylases could be a potential cure for AML. Methylstat is a chemical agent that inhibits the Jumonji C Domain-containing demethylases. The cytotoxic and apoptotic effect of Methylstat and Doxorubicin on HL-60 was detected by MTT cell viability assay, Double Staining of Treated Cells with Annexin-V/ Propidium Iodide (PI), and Caspase-3 Activity Assay, respectively. Also, mitochondrial activity was analyzed by using JC-1dye. The expression levels of BCL2 and BCL2L1 anti-apoptotic genes in HL-60 cells was determined by using Real-Time PCR. Lastly, the cytostatic effect was determined by cell cycle analysis. In our research, cytotoxic, cytostatic and apoptotic effects of Methylstat on human HL-60 cells was investigated. Cytotoxic and cytostatic analyses revealed that Methylstat decreased cell proliferation in a dose-dependent cytotoxic and arrested HL-60 cells in G2/M and S phases. Methylstat also induced apoptosis through the loss of mitochondrial membrane potential and increases in caspase 3 enzyme activity. Besides, the expression level of BCL2 and BCL2L1 were decreased according to Real-Time PCR results. Lastly, the combination of Methylstat with Doxorubicin resulted in synergistic cytotoxic effects on HL-60 cells. Taking together all these results demonstrated that Methylstat may be a powerful candidate to be a drug component to find the exact cure for AML.